

### **Remarks**

Claims 14-28 were pending. Claims 29-47 were added. Therefore, claims 14-48 are now pending.

### ***Amendments to the Specification***

The specification has been amended to remove hyperlinks, remove redundancies, and to correct obvious typographical errors.

As requested in the Communication, the specification has also been amended to include sequence identifiers for all amino acid sequences of four or more residues. In addition, a new sequence listing is enclosed that now includes SEQ ID NO: 42 (which was previously presented on page 4, line 27 of the specification).

### ***Amendments to the claims***

Support for the new claims can be found throughout the specification, for example:

Claims 29-38: claim 17 and page 5, lines 25-26.

Claim 39: page 11, lines 3-7.

Claim 40: page 17, lines 15-16.

Claims 41-42: page 4, lines 23-28.

Claim 43-44: original claim 3.

Claim 45: page 29, line 25- page 30, line 27.

Claims 46-48: page 32, line 20- page 34, line 21.

Claim 25 was amended to clarify the claim.


No new matter is added by this amendment. No amendments herein were made to distinguish prior art.

If there are any questions regarding this amendment, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 228-9446